文献速递肝病

质子泵抑制剂增加男性肝硬化患者骨折风险:一项基于人群的研究

Proton pump inhibitors increase risk of bone fractures in men with cirrhosis: a population-based study.
PubMed 文献 · Aliment Pharmacol Ther · 2020-07-30

该研究基于疾病分析数据库开展人群病例对照研究,比较1795例伴骨折肝硬化患者与10235例无骨折肝硬化患者。质子泵抑制剂使用与骨折相关(OR 1.34,95%CI 1.20-1.51,P<0.001),效应在男性和70岁以下患者中最强,并呈剂量依赖性。作者认为肝硬化患者使用质子泵抑制剂应基于仔细的风险-获益评估。

要点

  • 伴骨折肝硬化患者质子泵抑制剂使用率高于无骨折对照组(67.0% vs 53.4%,P<0.001)。
  • 调整混杂因素后质子泵抑制剂使用与骨折相关(OR 1.34,95%CI 1.20-1.51,P<0.001)。
  • 5年内累积剂量>50000 mg者效应最强(OR 1.63,95%CI 1.32-2.03)。

核心结论

  • 在肝硬化患者中,质子泵抑制剂使用与骨折呈剂量依赖性相关。
  • 作者认为肝硬化患者使用质子泵抑制剂应基于仔细的风险-获益评估。

研究设计与样本

  • 基于疾病分析数据库开展的人群病例对照研究,纳入肝硬化患者。
  • 共1795例伴骨折肝硬化患者与10235例无骨折肝硬化患者进行比较。
  • 分析索引日期前5年质子泵抑制剂总体使用及累积剂量,采用逻辑回归并考虑混杂因素。

主要发现

  • 伴骨折肝硬化患者质子泵抑制剂使用率为67.0%,无骨折对照组为53.4%(P<0.001)。
  • 调整重要混杂因素后,质子泵抑制剂使用与骨折相关(OR 1.34,95%CI 1.20-1.51,P<0.001)。
  • 质子泵抑制剂对骨折的效应在男性和70岁以下患者中最强。
  • 敏感性分析显示所有质子泵抑制剂均呈剂量依赖性效应,索引日期前5年累积剂量>50000 mg者效应最强(OR 1.63,95%CI 1.32-2.03)。

临床怎么用

  • 原文结论指出肝硬化患者使用质子泵抑制剂应基于仔细的风险-获益评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bone fractures are a frequent complication in patients with cirrhosis. Proton pump inhibitors (PPIs) are among the most frequently prescribed medications and may impair bone quality and quantity. AIMS: To investigate whether PPI use predisposes patients with cirrhosis to bone fractures. METHODS: We performed a population-based case-control study exploring a sample of patients with cirrhosis derived from the Disease Analyzer database. In total, 1795 cirrhotic patients with fractures were compared to 10 235 cirrhotic patients without fractures. PPI use overall and the cumulative PPI dose 5 years prior to the index date were analysed. To estimate the association between PPI use and fractures, logistic regression analyses were performed taking cofounding factors into consideration. RESULTS: PPI use was more frequently seen in cirrhotic patients with fractures compared to controls (67.0% vs 53.4%, P < 0.001). In regression analyses, PPI use was associated with bone fractures after adjusting for important confounders (OR 1.34, 95% CI 1.20-1.51, P < 0.001). Importantly, the strongest effect of PPIs on bone fractures was seen in men and patients below 70 years of age. On further sensitivity analyses, we observed a dose-dependent effect for all PPIs with the strongest effect in cirrhotic patients receiving a dose of >50 000 mg during the 5 years prior to index date (OR 1.63, 95% CI 1.32-2.03). CONCLUSIONS: PPI use was associated with bone fractures in a dose-dependent fashion in patients with cirrhosis. PPI use in these patients should be based on a careful risk-benefit assessment.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Labenz C, Wörns MA, Adarkwah CC, et al. Proton pump inhibitors increase risk of bone fractures in men with cirrhosis: a population-based study. Aliment Pharmacol Ther. 2020. PMID: 32729625. doi:10.1111/apt.16008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。